These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 7508663)

  • 21. The future of antigen-specific immunotherapy of allergy.
    Valenta R
    Nat Rev Immunol; 2002 Jun; 2(6):446-53. PubMed ID: 12093011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular and humoral mechanisms of immune tolerance in immediate-type allergy induced by specific immunotherapy.
    Möbs C; Slotosch C; Löffler H; Pfutzner W; Hertl M
    Int Arch Allergy Immunol; 2008; 147(3):171-8. PubMed ID: 18594146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation.
    Vrtala S; Ball T; Spitzauer S; Pandjaitan B; Suphioglu C; Knox B; Sperr WR; Valent P; Kraft D; Valenta R
    J Immunol; 1998 Jun; 160(12):6137-44. PubMed ID: 9637531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of folded recombinant Der p 5, a potential diagnostic marker allergen for house dust mite allergy.
    Weghofer M; Grote M; Dall'Antonia Y; Fernández-Caldas E; Krauth MT; van Hage M; Horak F; Thomas WR; Valent P; Keller W; Valenta R; Vrtala S
    Int Arch Allergy Immunol; 2008; 147(2):101-9. PubMed ID: 18520154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural rubber latex and hymenoptera venoms share ImmunoglobinE-epitopes accounting for cross-reactive carbohydrate determinants.
    Mahler V; Gutgesell C; Valenta R; Fuchs T
    Clin Exp Allergy; 2006 Nov; 36(11):1446-56. PubMed ID: 17083355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.
    Ball T; Linhart B; Sonneck K; Blatt K; Herrmann H; Valent P; Stoecklinger A; Lupinek C; Thalhamer J; Fedorov AA; Almo SC; Valenta R
    Allergy; 2009 Apr; 64(4):569-80. PubMed ID: 19243361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The value of immunotherapy in treatment of IgE-induced allergic diseases].
    Müller UR
    Ther Umsch; 1994 Jan; 51(1):67-76. PubMed ID: 7511841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
    Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment.
    Hiller R; Laffer S; Harwanegg C; Huber M; Schmidt WM; Twardosz A; Barletta B; Becker WM; Blaser K; Breiteneder H; Chapman M; Crameri R; Duchêne M; Ferreira F; Fiebig H; Hoffmann-Sommergruber K; King TP; Kleber-Janke T; Kurup VP; Lehrer SB; Lidholm J; Müller U; Pini C; Reese G; Scheiner O; Scheynius A; Shen HD; Spitzauer S; Suck R; Swoboda I; Thomas W; Tinghino R; Van Hage-Hamsten M; Virtanen T; Kraft D; Müller MW; Valenta R
    FASEB J; 2002 Mar; 16(3):414-6. PubMed ID: 11790727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of native, recombinant, and cross-reactive allergens on humoral and T-cell-mediated immune responses.
    Crameri R; Rhyner C
    Immunol Allergy Clin North Am; 2007 Feb; 27(1):65-78. PubMed ID: 17276879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Specific immunotherapy in allergies--evaluation of current status].
    Jarisch R; Hemmer W
    Wien Med Wochenschr; 1996; 146(15):422-5. PubMed ID: 9012204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnostic and therapeutic value of synthetic or recombinant allergens].
    Spertini F
    Rev Med Suisse Romande; 1999 Mar; 119(3):235-9. PubMed ID: 10218421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Animal models of type I allergy using recombinant allergens.
    Herz U; Renz H; Wiedermann U
    Methods; 2004 Mar; 32(3):271-80. PubMed ID: 14962762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant allergens for immunotherapy.
    Valenta R; Niederberger V
    J Allergy Clin Immunol; 2007 Apr; 119(4):826-30. PubMed ID: 17335886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decorating and loading ghosts with allergens for allergen immunotherapy.
    Fanuel S; Tabesh S; Rajani HF; Heidari S; Sadroddiny E; Kardar GA
    Hum Vaccin Immunother; 2017 Oct; 13(10):2428-2433. PubMed ID: 28934008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mechanisms of the effect of specific immunotherapy (hyposensitization) in atopic diseases].
    Fassakhov RS; Polsacheva OV; Zebrev AI; Rakhmatullin IM
    Patol Fiziol Eksp Ter; 1986; (4):66-9. PubMed ID: 3540819
    [No Abstract]   [Full Text] [Related]  

  • 37. Molecular approaches for new vaccines against allergy.
    Niederberger V; Valenta R
    Expert Rev Vaccines; 2006 Feb; 5(1):103-10. PubMed ID: 16451112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of allergen-specific immunotherapy.
    Akdis CA; Blaser K
    Allergy; 2000 Jun; 55(6):522-30. PubMed ID: 10858982
    [No Abstract]   [Full Text] [Related]  

  • 39. Recombinant allergens for diagnosis and therapy of allergic diseases.
    Valenta R; Kraft D
    Curr Opin Immunol; 1995 Dec; 7(6):751-6. PubMed ID: 8679115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy.
    Crameri R; Kündig TM; Akdis CA
    Curr Opin Allergy Clin Immunol; 2009 Dec; 9(6):568-73. PubMed ID: 19680120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.